New combo therapy targets liver tumors in advanced eye cancer

NCT ID NCT06626516

First seen Nov 01, 2025 · Last updated Jun 03, 2026 · Updated 31 times

Summary

This study tests a drug called tebentafusp combined with treatments that target liver tumors directly (like embolization or chemo-embolization) in people with a specific type of eye cancer (uveal melanoma) that has spread to the liver. The goal is to see if the combination is safe and works better than standard care. About 109 adults with a certain immune system marker (HLA-A*0201) will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.